Skip to main content
. Author manuscript; available in PMC: 2011 Jul 1.
Published in final edited form as: Immunobiology. 2009 Oct 31;215(7):535–544. doi: 10.1016/j.imbio.2009.09.006

Figure 1. CRCL induces the upregulation of the co-stimulatory molecule CD70 by DC.

Figure 1

(A) Day 5 bone marrow derived DC were treated with tumor-derived CRCL (25 μg/ml), or LPS (1 μg/ml) as positive control. (B) Similar as (A) but in presence of anti-CD40 antibody (5 μg/ml). After 48 hrs cells were stained with APC-conjugated anti-CD11c mAb and PE-conjugated anti-CD70 mAb and analyzed by flow cytometry. (A, B), Representative dot plots of three independent experiments. (C) Mean percent increase in CD70 expression by DC following the indicated treatments compared to untreated DC. *, a significant difference compared to DC treated with CRCL alone (p<0.05).